NOX Stock Overview
Noxopharm Limited, a drug development company, engages in the research and development of drugs for the treatment of cancer and prevention of septic shock in Australia and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.21|
|52 Week High||AU$0.81|
|52 Week Low||AU$0.20|
|1 Month Change||-33.85%|
|3 Month Change||-40.28%|
|1 Year Change||-63.56%|
|3 Year Change||-65.32%|
|5 Year Change||-43.42%|
|Change since IPO||16.22%|
Recent News & Updates
|NOX||AU Biotechs||AU Market|
Return vs Industry: NOX underperformed the Australian Biotechs industry which returned -8% over the past year.
Return vs Market: NOX underperformed the Australian Market which returned -0% over the past year.
|NOX Average Weekly Movement||11.7%|
|Biotechs Industry Average Movement||9.9%|
|Market Average Movement||9.3%|
|10% most volatile stocks in AU Market||16.3%|
|10% least volatile stocks in AU Market||4.2%|
Stable Share Price: NOX is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: NOX's weekly volatility (12%) has been stable over the past year.
About the Company
Noxopharm Limited, a drug development company, engages in the research and development of drugs for the treatment of cancer and prevention of septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries.
Noxopharm Fundamentals Summary
|NOX fundamental statistics|
Is NOX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NOX income statement (TTM)|
|Cost of Revenue||AU$12.59m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.038|
|Net Profit Margin||-185.98%|
How did NOX perform over the long term?See historical performance and comparison
How is Noxopharm forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Noxopharm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Noxopharm performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NOX is currently unprofitable.
Growing Profit Margin: NOX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NOX is unprofitable, but has reduced losses over the past 5 years at a rate of 8.6% per year.
Accelerating Growth: Unable to compare NOX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NOX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.7%).
Return on Equity
High ROE: NOX has a negative Return on Equity (-33.51%), as it is currently unprofitable.
How is Noxopharm's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: NOX's short term assets (A$25.1M) exceed its short term liabilities (A$2.3M).
Long Term Liabilities: NOX's short term assets (A$25.1M) exceed its long term liabilities (A$192.6K).
Debt to Equity History and Analysis
Debt Level: NOX is debt free.
Reducing Debt: NOX had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NOX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NOX has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 22.1% each year.
What is Noxopharm current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NOX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NOX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NOX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NOX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as NOX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Gisela Mautner serves as Chief Medical Officer at Noxopharm Limited since October 2019 and serves as its Chief Executive Officer and Executive Managing Director since February 01, 2022. Dr. Mautner has...
Experienced Management: NOX's management team is considered experienced (2.5 years average tenure).
Experienced Board: NOX's board of directors are considered experienced (4.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.8%.
Noxopharm Limited's employee growth, exchange listings and data sources
- Name: Noxopharm Limited
- Ticker: NOX
- Exchange: ASX
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: AU$62.831m
- Shares outstanding: 292.24m
- Website: https://www.noxopharm.com
Number of Employees
- Noxopharm Limited
- Tower A, The Zenith
- Level 20
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/25 00:00|
|End of Day Share Price||2022/05/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.